ICI + Bacterial Supplementation
Apr 20, 2023•12 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
We take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group.
We discuss what to look for in the future studies that are likely to follow with similar methods.
For the best experience, listen in Metacast app for iOS or Android